Experimental Sciences
Appilcation of polycaprolactone/collagen nanofibrous membranes in constituting tissue engineering retinal pigment epithelium
Tang Tian, Chen Jie, Deng Hua, Yin Xiaoguang, Fu Yan
Published 2019-11-10
Cite as Chin J Exp Ophthalmol, 2019, 37(11): 884-887. DOI: 10.3760/cma.j.issn.2095-0160.2019.11.007
Abstract
ObjectiveTo explore the potential of polycaprolactone (PCL)/gelatin nanofibrous composite membrane in constituting tissue engineering retinal pigment epithelium (RPE).
MethodsThe embryonic stem cells (ESCs) were differentiated into RPE (ESC-RPE) cells by spontaneous differentiation methods.Flow cytometry was used to detect the expression of specific RPE markers in ESC-RPE cells.The nanofiber membrane of PCL and PCL/gelatin nanofibrous composite membrane were prepared by electrospinning.The topography and contact angle of the two membranes were detected.The viability of ESC-RPE cells treated by the extracts of the two kinds of membranes was detected by cell counting kit-8 (CCK-8)method.After the ESC-RPE cells were cultured on the PCL/gelatin nanofibrous composite membrane, immunostaining was used to detect the expression of specific RPE markers of tissue engineering RPE.
ResultsESC-RPE cells were negative for pluripotent marker OCT4, but positive for microphthalmia-associated transcription factor (MITF), RPE65 and Bestrophin.Both the nanofiber membrane of PCL and PCL/gelatin nanofibrous composite membrane were porous and the contact angle were (97.2±3.1)° and (13.6±2.4)°, respectively.The extracts of the two kinds of membranes showed no significant effect on the growth of ESC-RPE cells.The tissue engineering RPE based on PCL/gelatin nanofibrous composite membrane positively expressed MITF and ZO-1.
ConclusionsPCL/gelatin nanofibrous composite membrane shows good hydrophilicity and biocompatibility.Besides, the membrane is favor for the growth of ESC-RPE cells and holds the potential to constitute tissue engineering RPE.
Key words:
Retinal pigment epithelium; Retinal degeneration diseases; Polycaprolactone; Collagen; Tissue engineering
Contributor Information
Tang Tian
Second Outpatient Department, The General Hospital of Western Theater Command, Chengdu 610083, China
Chen Jie
Second Outpatient Department, The General Hospital of Western Theater Command, Chengdu 610083, China
Deng Hua
Second Outpatient Department, The General Hospital of Western Theater Command, Chengdu 610083, China
Yin Xiaoguang
Chongqing Sidemu Biological Technology Company Limited, Chongqing 400026, China
Fu Yan
Second Outpatient Department, The General Hospital of Western Theater Command, Chengdu 610083, China
